Andrew Eugene Hendifar

Title(s)HS Associate Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. ctDNA-guided adjuvant immunotherapy in colorectal cancer. Immunotherapy. 2024 Nov 17; 1-6. Burley N, Lee Y, Liu L, Gangi A, Nasseri Y, Atkins K, Zaghiyan K, Murrell Z, Osipov A, Hendifar A, Hitchins M, Gong J. PMID: 39552190.
      View in: PubMed   Mentions:    Fields:    
    2. A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy. Oncotarget. 2024 Oct 11; 15:741-747. Ahmed M, Larson BK, Osipov A, Azad N, Hendifar A. PMID: 39392392; PMCID: PMC11468600.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024 Sep 14. Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, Dunne RF, Karahanoglu I, Northcott CA, Harrington MA, Rossulek M, Qiu R, Saxena AR. PMID: 39282907.
      View in: PubMed   Mentions: 3     Fields:    
    4. Incidence Trends in Upper Gastrointestinal Cancer in Young Adults: A Nationwide Time-Trend Analysis Using 2001-2019 US Cancer Statistics Databases. Am J Gastroenterol. 2024 Sep 03. Liang J, Rastegar R, El Helou M, Mathur K, Larson BK, Waters K, Vasireddy A, Randhawa N, Mubarak M, Advani R, Osipov A, Gong J, Hendifar A, Liu Q, Park KH, Watson R, Pandol SJ, Lo S, Gaddam S. PMID: 39225338.
      View in: PubMed   Mentions:    Fields:    
    5. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Am J Clin Pathol. 2024 Sep 03; 162(3):314-326. Delgado-Coka LA, Roa-Peña L, Babu S, Horowitz M, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Akalin A, Jiang W, Larson BK, Hendifar AE, Picozzi VJ, Choi M, Shroyer KR, Escobar-Hoyos LF. PMID: 38642081; PMCID: PMC11369068.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Low booster uptake in cancer patients despite health benefits. iScience. 2024 Sep 20; 27(9):110596. Figueiredo JC, Levy J, Choi SY, Xu AM, Merin NM, Hamid O, Lemos T, Nguyen N, Nadri M, Gonzalez A, Mahov S, Darrah JM, Gong J, Paquette RL, Mita AC, Vescio RA, Salvy SJ, Mehmi I, Hendifar AE, Natale R, Tourtellotte WG, Ramanujan VK, Huynh CA, Sobhani K, Reckamp KL, Merchant AA. PMID: 39286512; PMCID: PMC11404159.
      View in: PubMed   Mentions:
    7. 5-Hydroxymethylcytosine (5-hmC) loss is a marker of malignancy in biliary neoplasms. Am J Clin Pathol. 2024 Jul 05; 162(1):41-50. Gonzalez-Mancera MS, Siref A, Kosari K, Nissen N, Gaddam S, Hendifar A, Osipov A, Waters K, Hutchings D, Guindi M, Larson BK. PMID: 38345293.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study. Clin Transl Gastroenterol. 2024 Jul 01; 15(7):e00719. Wang J, Cui Y, Osipov A, Gong J, Pandol S, Lo S, Nissen N, Abbas A, Levi A, Hendifar A. PMID: 38822798; PMCID: PMC11272255.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Development and validation of a biomarker index for HCC treatment response. Hepatol Commun. 2024 07 01; 8(7). Liang J, Li PY, Norman J, Lauzon M, Yeo YH, Trivedi H, Ayoub WS, Kuo A, Friedman ML, Sankar K, Gong J, Osipov A, Hendifar A, Todo T, Kim I, Voidonikolas G, Brennan TV, Wisel SA, Steggarda J, Kosari K, Saouaf R, Nissen N, Yao F, Mehta N, Yang JD. PMID: 38896084; PMCID: PMC11186807.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. High frequency of germline variants in CFTR identified in PDAC patients enrolled in an expanded panel multi-gene panel testing program. HPB (Oxford). 2024 08; 26(8):1082-1085. Hendifar A, Hitchins M, Lauzon M, Hatchell KE, Heald B, Pandol S, Naren AP, Osipov A. PMID: 38825435; PMCID: PMC11317177.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas. J Neuroendocrinol. 2024 Aug; 36(8):e13399. Russo A, DiPeri T, Dumitra T, Tseng J, Pletcher E, Justo M, Chen C, Nissen N, Amersi F, Gong J, Hendifar A, Gangi A. PMID: 38760997.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Keratin 17 modulates the immune topography of pancreatic cancer. J Transl Med. 2024 May 10; 22(1):443. Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Peña L, Leiton CV, Hasan M, Babu S, Fassler D, Oentoro J, Bai JK, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos LF, Shroyer KR. PMID: 38730319; PMCID: PMC11087249.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    13. Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention. Cancers (Basel). 2024 Mar 05; 16(5). Muranaka H, Akinsola R, Billet S, Pandol SJ, Hendifar AE, Bhowmick NA, Gong J. PMID: 38473414; PMCID: PMC10930819.
      View in: PubMed   Mentions: 2  
    14. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Using 2001-2018 United States Cancer Statistics Databases. Cancers (Basel). 2024 Feb 28; 16(5). Jiang Y, Abboud Y, Liang J, Larson B, Osipov A, Gong J, Hendifar AE, Atkins K, Liu Q, Nissen NN, Li D, Pandol SJ, Lo SK, Gaddam S. PMID: 38473332; PMCID: PMC10931165.
      View in: PubMed   Mentions: 2  
    15. Keratin 17 modulates the immune topography of pancreatic cancer. Res Sq. 2024 Feb 20. Delgado-Coka LA, Horowitz M, Torrente-Goncalves M, Roa-Peña L, Leiton CV, Hasan M, Babu S, Fassler D, Oentoro J, Karen Bai JD, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos LF, Shroyer K. PMID: 38464123; PMCID: PMC10925455.
      View in: PubMed   Mentions:
    16. Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. NPJ Precis Oncol. 2024 Feb 15; 8(1):36. Shishido SN, Lin E, Nissen N, Courcoubetis G, Suresh D, Mason J, Osipov A, Hendifar AE, Lewis M, Gaddam S, Pandol S, Kuhn P, Lo SK. PMID: 38360856; PMCID: PMC10869814.
      View in: PubMed   Mentions: 3  
    17. Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation Therapy. Adv Radiat Oncol. 2024 May; 9(5):101471. Chung EM, Lu DJ, Nguyen AT, Hendifar AE, Nissen NN, Gong J, Osipov A, Gangi A, Attiyeh MA, Atkins KM, Kamrava M. PMID: 38550374; PMCID: PMC10965432.
      View in: PubMed   Mentions:
    18. The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients. Nat Cancer. 2024 Feb; 5(2):299-314. Osipov A, Nikolic O, Gertych A, Parker S, Hendifar A, Singh P, Filippova D, Dagliyan G, Ferrone CR, Zheng L, Moore JH, Tourtellotte W, Van Eyk JE, Theodorescu D. PMID: 38253803; PMCID: PMC10899109.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    19. Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivity. Res Sq. 2023 Nov 30. Muranaka H, Billet S, Cruz-Hernández C, Ten Hoeve J, Gonzales G, Elmadbouh O, Zhang L, Smith B, Tighiouart M, You S, Edderkaoui M, Hendifar A, Pandol S, Gong J, Bhowmick N. PMID: 38076821; PMCID: PMC10705710.
      View in: PubMed   Mentions:
    20. COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States. Gastro Hep Adv. 2024; 3(2):230-237. Kaur B, Yeo YH, Liang J, Luu M, Ayoub W, Kuo A, Trivedi H, Sankar K, Gong J, Hendifar A, Osipov A, Kosari K, Nissen N, Noureddin M, Singal AG, Yang JD. PMID: 39129956; PMCID: PMC11308067.
      View in: PubMed   Mentions:
    21. Low booster uptake in cancer patients despite health benefits. medRxiv. 2023 Oct 26. Figueiredo JC, Levy J, Choi SY, Xu AM, Merin NM, Hamid O, Lemos T, Nguyen N, Nadri M, Gonzalez A, Mahov S, Darrah JM, Gong J, Paquette RL, Mita AC, Vescio RA, Salvy SJ, Mehmi I, Hendifar AE, Natale R, Tourtellotte WG, Krishnan Ramanujan V, Huynh CA, Sobhani K, Reckamp KL, Merchant AA. PMID: 37961284; PMCID: PMC10635201.
      View in: PubMed   Mentions:
    22. Socioeconomic disparities in patients with small bowel neuroendocrine tumors. J Surg Oncol. 2023 Dec; 128(8):1278-1284. DiPeri TP, Manguso N, Gong J, Atkins KM, Hendifar AE, Gangi A. PMID: 37668060.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma. Am J Gastroenterol. 2023 12 01; 118(12):2201-2211. Yeo YH, Liang J, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, Sankar K, Gong J, Hendifar A, Osipov A, Friedman ML, Lipshutz HG, Steinberger J, Kosari K, Nissen N, Abou-Alfa GK, Singal AG, Yang JD. PMID: 37561061.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    24. Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2024 Jan; 30(1):1-15. Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, Hendifar AE, Koltsova EK, Yang JD. PMID: 37482076; PMCID: PMC10776289.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    25. Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. Cancers (Basel). 2023 Jun 01; 15(11). Muranaka H, Hendifar A, Osipov A, Moshayedi N, Placencio-Hickok V, Tatonetti N, Stotland A, Parker S, Van Eyk J, Pandol SJ, Bhowmick NA, Gong J. PMID: 37296982; PMCID: PMC10252041.
      View in: PubMed   Mentions: 3  
    26. POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval. Genes (Basel). 2023 05 08; 14(5). Bikhchandani M, Amersi F, Hendifar A, Gangi A, Osipov A, Zaghiyan K, Atkins K, Cho M, Aguirre F, Hazelett D, Alvarez R, Zhou L, Hitchins M, Gong J. PMID: 37239414; PMCID: PMC10218075.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    27. Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol. Biomedicines. 2023 May 08; 11(5). Gong J, Osipov A, Lorber J, Tighiouart M, Kwan AK, Muranaka H, Akinsola R, Billet S, Levi A, Abbas A, Davelaar J, Bhowmick N, Hendifar AE. PMID: 37239063; PMCID: PMC10216251.
      View in: PubMed   Mentions: 2  
    28. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Cell Rep Med. 2023 04 18; 4(4):101013. Nimgaonkar V, Krishna V, Krishna V, Tiu E, Joshi A, Vrabac D, Bhambhvani H, Smith K, Johansen JS, Makawita S, Musher B, Mehta A, Hendifar A, Wainberg Z, Sohal D, Fountzilas C, Singhi A, Rajpurkar P, Collisson EA. PMID: 37044094; PMCID: PMC10140610.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    29. TOPAZ-1: a new standard of care for advanced biliary tract cancers? Immunotherapy. 2023 05; 15(7):473-476. Ebia MI, Sankar K, Osipov A, Hendifar AE, Gong J. PMID: 36950948.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    30. Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma. J Gastrointest Oncol. 2023 Apr 29; 14(2):1175-1177. Ebia MI, Hitchins MP, Hendifar AE. PMID: 37201064; PMCID: PMC10186511.
      View in: PubMed   Mentions: 1  
    31. Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical Outcome. Pancreas. 2023 Mar 01; 52(3):e179-e187. Sharma NR, Lo SK, Hendifar A, Othman MO, Patel K, Mendoza-Ladd A, Verco S, Maulhardt HA, Verco J, Wendt A, Marin A, Schmidt CM, diZerega G. PMID: 37782888.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    32. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018. Gastroenterology. 2023 05; 164(6):978-989.e6. Abboud Y, Samaan JS, Oh J, Jiang Y, Randhawa N, Lew D, Ghaith J, Pala P, Leyson C, Watson R, Liu Q, Park K, Paski S, Osipov A, Larson BK, Hendifar A, Atkins K, Nissen NN, Li D, Pandol SJ, Lo SK, Gaddam S. PMID: 36775072; PMCID: PMC11364483.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    33. Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000-2018. Cancers (Basel). 2023 Jan 31; 15(3). Samaan JS, Abboud Y, Oh J, Jiang Y, Watson R, Park K, Liu Q, Atkins K, Hendifar A, Gong J, Osipov A, Li D, Nissen NN, Pandol SJ, Lo SK, Gaddam S. PMID: 36765827; PMCID: PMC9913805.
      View in: PubMed   Mentions: 11  
    34. Multitasking dynamic contrast enhanced magnetic resonance imaging can accurately differentiate chronic pancreatitis from pancreatic ductal adenocarcinoma. Front Oncol. 2022; 12:1007134. Wang N, Gaddam S, Xie Y, Christodoulou AG, Wu C, Ma S, Fan Z, Wang L, Lo S, Hendifar AE, Pandol SJ, Li D. PMID: 36686811; PMCID: PMC9853434.
      View in: PubMed   Mentions: 1  
    35. Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS. Cancers (Basel). 2022 Dec 30; 15(1). Vogelaar IP, Greer S, Wang F, Shin G, Lau B, Hu Y, Haraldsdottir S, Alvarez R, Hazelett D, Nguyen P, Aguirre FP, Guindi M, Hendifar A, Balcom J, Leininger A, Fairbank B, Ji H, Hitchins MP. PMID: 36612224; PMCID: PMC9818763.
      View in: PubMed   Mentions: 1  
    36. Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma. J Natl Compr Canc Netw. 2022 11 17; 21(1):6-11. Chen L, Davelaar J, Gaddam S, Kosari K, Nissen N, Chaux G, Lee C, Vail E, Hendifar A, Gong J, Reckamp K, Osipov A. PMID: 36395704.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Nov 04; 12(1):18731. Gong J, Thomassian S, Kim S, Gresham G, Moshayedi N, Ye JY, Yang JC, Jacobs JP, Lo S, Nissen N, Gaddam S, Tighiouart M, Osipov A, Hendifar A. PMID: 36333397; PMCID: PMC9636406.
      View in: PubMed   Mentions:    Fields:    
    38. Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study. Oncotarget. 2022 Nov 02; 13:1202-1214. Gong J, Guan M, Kim H, Moshayedi N, Mehta S, Cook-Wiens G, Larson BK, Zhou J, Patel R, Lapite I, Placencio-Hickok VR, Tuli R, Natale RB, Hendifar AE. PMID: 36342462; PMCID: PMC9629814.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Pancreatoblastoma in Elderly Adults: Report of Two Patients. Int J Surg Pathol. 2023 Aug; 31(5):772-777. Kulak O, Osipov A, Hendifar AE, Nissen NN, Cox BK, Hruban RH, Hutchings DA. PMID: 36314453.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. Invest New Drugs. 2022 12; 40(6):1306-1314. Rajdev L, Lee JW, Libutti SK, Benson AB, Fisher GA, Kunz PL, Hendifar AE, Catalano P, O'Dwyer PJ. PMID: 36264382; PMCID: PMC9795724.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    41. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023 03 01; 41(7):1359-1369. Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB. PMID: 36260828; PMCID: PMC9995105.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    42. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2022 10; 20(10):1076-1079. Ng CF, Glaspy J, Placencio-Hickok VR, Thomassian S, Gong J, Osipov A, Hendifar AE, Moshayedi N. PMID: 36240849.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    43. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Sep 02; 12(1):15013. Gong J, Thomassian S, Kim S, Gresham G, Moshayedi N, Ye JY, Yang JC, Jacobs JP, Lo S, Nissen N, Gaddam S, Tighiouart M, Osipov A, Hendifar A. PMID: 36056179; PMCID: PMC9440135.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    44. Gut microbiome and pancreatic cancer cachexia: An evolving relationship. World J Gastrointest Oncol. 2022 Jul 15; 14(7):1218-1226. Hendifar A, Akinsola R, Muranaka H, Osipov A, Thomassian S, Moshayedi N, Yang J, Jacobs J, Devkota S, Bhowmick N, Gong J. PMID: 36051103; PMCID: PMC9305570.
      View in: PubMed   Mentions: 1  
    45. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Gastroenterology. 2022 11; 163(5):1267-1280.e7. Blair AB, Wang J, Davelaar J, Baker A, Li K, Niu N, Wang J, Shao Y, Funes V, Li P, Pachter JA, Maneval DC, Dezem F, Plummer J, Chan KS, Gong J, Hendifar AE, Pandol SJ, Burkhart R, Zhang Y, Zheng L, Osipov A. PMID: 35718227; PMCID: PMC9613523.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
    46. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clin Cancer Res. 2022 06 13; 28(12):2704-2714. Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, Hwang JJ, Gong J, Feldman R, Ellis M, Stafford P, Spetzler D, Khushman MM, Sohal D, Lockhart AC, Weinberg BA, El-Deiry WS, Marshall J, Shields AF, Korn WM. PMID: 35302596; PMCID: PMC9541577.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    47. Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation. Pancreas. 2022 05 01; 51(5):463-468. Wang L, Zhou Z, Gaddam S, Wang N, Xie Y, Deng Z, Fan Z, Christodoulou AG, Han F, Lo SK, Wachsman AM, Hendifar AE, Jiang T, Pandol SJ, Li D. PMID: 35858211.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Claudin-18. Arch Pathol Lab Med. 2022 05 01; 147(5):559-567. Wong MT, Singhi AD, Larson BK, Huynh CAT, Balzer BL, Burch M, Dhall D, Gangi A, Gong J, Guindi M, Hendifar AE, Kim SA, de Peralta-Venturina M, Waters KM. PMID: 35976638.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology. 2022 12; 76(6):1649-1659. Ahn JC, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, Sundaram V, Kosari K, Nissen N, Gong J, Hendifar A, Roberts LR, Abou-Alfa GK, Singal AG, Yang JD. PMID: 35429171.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    50. Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. Diseases. 2022 Apr 19; 10(2). Chuang J, Klempner S, Waters K, Atkins K, Chao J, Cho M, Hendifar A, Gangi A, Burch M, Mehta P, Gong J. PMID: 35645244; PMCID: PMC9149813.
      View in: PubMed   Mentions: 2  
    51. ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. JCO Precis Oncol. 2022 04; 6:e2200015. Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F. PMID: 35476549; PMCID: PMC9200393.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    52. Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer. Mol Clin Oncol. 2022 May; 16(5):100. Gong J, Aguirre F, Hazelett D, Alvarez R, Zhou L, Hendifar A, Osipov A, Zaghiyan K, Cho M, Gangi A, Hitchins M. PMID: 35463213; PMCID: PMC9022091.
      View in: PubMed   Mentions: 3  
    53. Lung Neuroendocrine Tumors: How Does Molecular Profiling Help? Curr Oncol Rep. 2022 07; 24(7):819-824. Sun TY, Hendifar A, Padda SK. PMID: 35305210.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    54. Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. Pancreas. 2022 03 01; 51(3):213-218. Hendifar AE, Mehr SH, McHaffie DR. PMID: 35584377; PMCID: PMC9119402.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    55. Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop. J Cachexia Sarcopenia Muscle. 2022 04; 13(2):1418-1425. Garcia JM, Dunne RF, Santiago K, Martin L, Birnbaum MJ, Crawford J, Hendifar AE, Kochanczyk M, Moravek C, Piccinin D, Picozzi V, Roeland EJ, Selig WKD, Zimmers TA. PMID: 35218313; PMCID: PMC8978010.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    56. Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. World J Gastrointest Oncol. 2022 Feb 15; 14(2):511-524. Midthun L, Kim S, Hendifar A, Osipov A, Klempner SJ, Chao J, Cho M, Guan M, Placencio-Hickok VR, Gangi A, Burch M, Lin DC, Waters K, Atkins K, Kamrava M, Gong J. PMID: 35317320; PMCID: PMC8919005.
      View in: PubMed   Mentions:
    57. A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. JAMA Netw Open. 2021 12 01; 4(12):e2138432. Anderson E, LeVee A, Kim S, Atkins K, Guan M, Placencio-Hickok V, Moshayedi N, Hendifar A, Osipov A, Gangi A, Burch M, Waters K, Cho M, Klempner S, Chao J, Kamrava M, Gong J. PMID: 34889947; PMCID: PMC8665367.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    58. Correction to: Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection. Ann Surg Oncol. 2021 Dec; 28(Suppl 3):872. Gangi A, Manguso N, Gong J, Crystal JS, Paski SC, Hendifar AE, Tuli R. PMID: 33751301.
      View in: PubMed   Mentions:    Fields:    
    59. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 12; 22(12):1752-1763. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP, NETTER-1 investigators. PMID: 34793718.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCTClinical Trials
    60. Advances in Pancreatic Ductal Adenocarcinoma Treatment. Cancers (Basel). 2021 Nov 03; 13(21). Anderson EM, Thomassian S, Gong J, Hendifar A, Osipov A. PMID: 34771675; PMCID: PMC8583016.
      View in: PubMed   Mentions: 19  
    61. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021 10 08; 7(41):eabi7511. Kurth I, Yamaguchi N, Andreu-Agullo C, Tian HS, Sridhar S, Takeda S, Gonsalves FC, Loo JM, Barlas A, Manova-Todorova K, Busby R, Bendell JC, Strauss J, Fakih M, McRee AJ, Hendifar AE, Rosen LS, Cercek A, Wasserman R, Szarek M, Spector SL, Raza S, Tavazoie MF, Tavazoie SF. PMID: 34613776; PMCID: PMC8494442.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    62. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. J Cachexia Sarcopenia Muscle. 2021 12; 12(6):1959-1968. Gresham G, Placencio-Hickok VR, Lauzon M, Nguyen T, Kim H, Mehta S, Paski S, Pandol SJ, Osipov A, Gong J, Jamil LH, Nissen N, Lo SK, Hendifar AE. PMID: 34609081; PMCID: PMC8718084.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    63. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Pancreatology. 2022 Jan; 22(1):92-97. Placencio-Hickok VR, Lauzon M, Moshayedi N, Guan M, Kim S, Nissen N, Lo S, Pandol S, Larson BK, Gong J, Hendifar AE, Osipov A. PMID: 34657790; PMCID: PMC8903049.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer. Cancers (Basel). 2021 Sep 10; 13(18). Gong J, Hendifar A, Gangi A, Zaghiyan K, Atkins K, Nasseri Y, Murrell Z, Figueiredo JC, Salvy S, Haile R, Hitchins M. PMID: 34572774; PMCID: PMC8471730.
      View in: PubMed   Mentions: 9  
    65. Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience. Cancer Med. 2021 10; 10(20):7152-7161. Gupta A, Khalid O, Moravek C, Lamkin A, Matrisian LM, Doss S, Denlinger CS, Coveler AL, Weekes CD, Roeland EJ, Hendifar AE, Nipp RD. PMID: 34477302; PMCID: PMC8525124.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    66. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol. 2021; 5. Hendifar A, Blais EM, Wolpin B, Subbiah V, Collisson E, Singh I, Cannon T, Shaw K, Petricoin EF, Klempner S, Lyons E, Wang-Gillam A, Pishvaian MJ, O'Reilly EM. PMID: 34476331; PMCID: PMC8407652.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    67. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 05; 5(1):74. Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. PMID: 34354225; PMCID: PMC8342450.
      View in: PubMed   Mentions: 28  
    68. Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset. Cancers (Basel). 2021 Jul 29; 13(15). Himbert C, Figueiredo JC, Shibata D, Ose J, Lin T, Huang LC, Peoples AR, Scaife CL, Pickron B, Lambert L, Cohan JN, Bronner M, Felder S, Sanchez J, Dessureault S, Coppola D, Hoffman DM, Nasseri YF, Decker RW, Zaghiyan K, Murrell ZA, Hendifar A, Gong J, Firoozmand E, Gangi A, Moore BA, Cologne KG, El-Masry MS, Hinkle N, Monroe J, Mutch M, Bernadt C, Chatterjee D, Sinanan M, Cohen SA, Wallin U, Grady WM, Lampe PD, Reddi D, Krane M, Fichera A, Moonka R, Herpel E, Schirmacher P, Kloor M, von Knebel-Doeberitz M, Nattenmueller J, Kauczor HU, Swanson E, Jedrzkiewicz J, Schmit SL, Gigic B, Ulrich AB, Toriola AT, Siegel EM, Li CI, Ulrich CM, Hardikar S. PMID: 34359718; PMCID: PMC8345133.
      View in: PubMed   Mentions: 13  
    69. Complete response to neoadjuvant pembrolizumab and capecitabine in microsatellite stable, Epstein-Barr virus-positive, locally advanced gastric adenocarcinoma: case report. AME Case Rep. 2021; 5:30. Lin CY, Mehta P, Waters KM, Chang E, Hendifar A, Osipov A, Burch M, Lin DC, Gangi A, Cho M, Gong J. PMID: 34312609; PMCID: PMC8256116.
      View in: PubMed   Mentions: 3  
    70. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. Front Oncol. 2021; 11:678070. Yu KH, Hendifar AE, Alese OB, Draper A, Abdelrahim M, Burns E, Khan G, Cockrum P, Bhak RH, Nguyen C, DerSarkissian M, Duh MS, Bahary N. PMID: 34336666; PMCID: PMC8319949.
      View in: PubMed   Mentions: 4  
    71. Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9). Singh A, Beechinor RJ, Huynh JC, Li D, Dayyani F, Valerin JB, Hendifar A, Gong J, Cho M. PMID: 33946408; PMCID: PMC8125389.
      View in: PubMed   Mentions: 8  
    72. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Nov; 28(12):7545-7554. Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC. PMID: 33813673.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    73. Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations. Cancers (Basel). 2021 Apr 03; 13(7). Lee PC, Hendifar A, Osipov A, Cho M, Li D, Gong J. PMID: 33916849; PMCID: PMC8038487.
      View in: PubMed   Mentions: 13  
    74. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE. J Nucl Med. 2021 Mar 26. Strosberg JR, Srirajaskanthan R, El-Haddad G, Wolin EM, Chasen BR, Kulke MH, Bushnell DL, Caplin ME, Baum RP, Hendifar AE, Öberg K, Ruszniewski P, Santoro P, Broberg P, Leeuwenkamp OR, Krenning EP. PMID: 33771903; PMCID: PMC8612179.
      View in: PubMed   Mentions: 6     Fields:    
    75. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021 05; 32(5):600-608. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G, James D, Macarulla T. PMID: 33539945.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    76. Symptom Management in Pancreatic Cancer. Curr Treat Options Oncol. 2021 01 02; 22(1):8. Lee KG, Roy V, Laszlo M, Atkins KM, Lin KJ, Tomassian S, Hendifar AE. PMID: 33387071.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    77. Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma. Therap Adv Gastroenterol. 2020; 13:1756284820964319. Gong J, Guan M, Forsmark CE, Petzel MQ, Placencio-Hickok V, Hendifar A. PMID: 33354227; PMCID: PMC7734497.
      View in: PubMed   Mentions: 1  
    78. Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case. JCO Precis Oncol. 2020 Nov; 4:614-619. Klempner SJ, Hendifar A, Waters KM, Nissen N, Vail E, Tuli R, Mita A. PMID: 35050748.
      View in: PubMed   Mentions: 6     Fields:    
    79. Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. World J Gastrointest Surg. 2020 Sep 27; 12(9):377-389. Kim S, DiPeri TP, Guan M, Placencio-Hickok VR, Kim H, Liu JY, Hendifar A, Klempner SJ, Nipp R, Gangi A, Burch M, Waters K, Cho M, Chao J, Atkins K, Kamrava M, Tuli R, Gong J. PMID: 33024512; PMCID: PMC7520571.
      View in: PubMed   Mentions: 4  
    80. Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis. J Natl Compr Canc Netw. 2020 09; 18(9):1210-1220. Yang JD, Luu M, Singal AG, Noureddin M, Kuo A, Ayoub WS, Sundaram V, Kotler H, Kim IK, Todo T, Voidonikolas G, Brennan TV, Kosari K, Klein AS, Hendifar A, Lu SC, Nissen NN, Gong J. PMID: 32886898.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    81. Remote Oncology Care: Review of Current Technology and Future Directions. Cureus. 2020 Aug 31; 12(8):e10156. McGregor BA, Vidal GA, Shah SA, Mitchell JD, Hendifar AE. PMID: 33014652; PMCID: PMC7526951.
      View in: PubMed   Mentions: 9  
    82. Priority Rankings of Patient-Reported Outcomes for Pancreatic Ductal Adenocarcinoma: A Comparison of Patient and Physician Perspectives. J Natl Compr Canc Netw. 2020 08; 18(8):1075-1083. Guan M, Gresham G, Shinde A, Lapite I, Gong J, Placencio-Hickok VR, Forrest CB, Hendifar AE. PMID: 32755983.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    83. Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib. JCO Precis Oncol. 2020; 4. Gower A, Golestany B, Gong J, Singhi AD, Hendifar AE. PMID: 32923899; PMCID: PMC7446504.
      View in: PubMed   Mentions: 11     Fields:    
    84. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020 09 20; 38(27):3185-3194. Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ, HALO 109-301 Investigators. PMID: 32706635; PMCID: PMC7499614.
      View in: PubMed   Mentions: 171     Fields:    Translation:HumansCTClinical Trials
    85. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci. 2020 Jul 23; 21(15). Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. PMID: 32718047; PMCID: PMC7432744.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    86. Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. JCO Precis Oncol. 2020; 4. Gong J, Patel S, Adashek JJ, Frishberg D, Guan M, Placencio-Hickok VR, Gangi A, Gresham G, Tuli R, Chae YK, Kurzrock R, Hendifar AE. PMID: 33215052; PMCID: PMC7670562.
      View in: PubMed   Mentions: 1     Fields:    
    87. Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection. Ann Surg Oncol. 2020 Oct; 27(11):4525-4532. Gangi A, Manguso N, Gong J, Crystal JS, Paski SC, Hendifar AE, Tuli R. PMID: 32394299.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    88. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. Cancers (Basel). 2020 May 06; 12(5). Huynh JC, Schwab E, Ji J, Kim E, Joseph A, Hendifar A, Cho M, Gong J. PMID: 32384640; PMCID: PMC7281439.
      View in: PubMed   Mentions: 2  
    89. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 09; 47(10):2372-2382. Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E, NETTER-1 study group. PMID: 32123969; PMCID: PMC7396396.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    90. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020 04; 21(4):508-518. Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, Petricoin EF. PMID: 32135080; PMCID: PMC7453743.
      View in: PubMed   Mentions: 208     Fields:    Translation:Humans
    91. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. Pancreas. 2020 03; 49(3):393-407. Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY. PMID: 32132518; PMCID: PMC7077976.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    92. Multiparametric Mapping Magnetic Resonance Imaging of Pancreatic Disease. Front Physiol. 2020; 11:8. Wang L, Gaddam S, Wang N, Xie Y, Deng Z, Zhou Z, Fan Z, Jiang T, Christodoulou AG, Han F, Lo SK, Wachsman AM, Hendifar AE, Pandol SJ, Li D. PMID: 32153416; PMCID: PMC7047169.
      View in: PubMed   Mentions: 12  
    93. Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder. Pancreas. 2020 02; 49(2):e19-e20. Chorath J, Placencio-Hickok VR, Guan M, Nissen N, Kamrava M, Klempner SJ, Nassir Y, Hendifar A, Gong J. PMID: 32049953.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    94. Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. Magn Reson Med. 2020 08; 84(2):928-948. Wang N, Gaddam S, Wang L, Xie Y, Fan Z, Yang W, Tuli R, Lo S, Hendifar A, Pandol S, Christodoulou AG, Li D. PMID: 31961967; PMCID: PMC7323577.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    95. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound. 2020 Jan-Feb; 9(1):24-30. Bhutani MS, Klapman JB, Tuli R, El-Haddad G, Hoffe S, Wong FCL, Chasen B, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MHG, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. PMID: 31670288; PMCID: PMC7038730.
      View in: PubMed   Mentions: 13  
    96. A radiopaque polymer hydrogel as an irreversible electroporation compatible fiducial marker for pancreas stereotactic body radiotherapy. J Radiosurg SBRT. 2020; 7(2):165-167. Anderson EM, Park K, Lu DJ, Nissen N, Gong J, Hendifar A, Gangi A, Lo S, Kamrava M, Atkins KM. PMID: 33282470; PMCID: PMC7717092.
      View in: PubMed   Mentions:
    97. Raynaud's Phenomenon From PD-1 Immune Checkpoint Inhibition. JCO Oncol Pract. 2020 10; 16(10):701-702. Kim H, Jones AJ, Labadzhyan A, Placencio-Hickok VR, Wallace DJ, Gong J, Hendifar AE. PMID: 31790328.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    98. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. JCO Precis Oncol. 2019 Dec; 3:1-10. Pishvaian MJ, Blais EM, Brody JR, Rahib L, Lyons E, De Arbeloa P, Hendifar A, Mikhail S, Chung V, Sohal DPS, Leslie S, Mason K, Tibbets L, Madhavan S, Matrisian LM, Petricoin E. PMID: 35100730.
      View in: PubMed   Mentions: 52     Fields:    
    99. Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. Oncotarget. 2019 Oct 22; 10(58):6260-6268. Gong J, Blais EM, Bender JR, Guan M, Placencio-Hickok V, Petricoin EF, Pishvaian MJ, Gregory G, Tuli R, Hendifar AE. PMID: 31692857; PMCID: PMC6817448.
      View in: PubMed   Mentions: 2     Fields:    
    100. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open. 2019 Dec; 2(4):505-515. Pishvaian MJ, Blais EM, Bender RJ, Rao S, Boca SM, Chung V, Hendifar AE, Mikhail S, Sohal DPS, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Halverson DD, DeArbeloa P, Petricoin EF, Madhavan S. PMID: 32025647; PMCID: PMC6994017.
      View in: PubMed   Mentions: 36  
    101. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precis Oncol. 2019; 3. Clifton K, Rich TA, Parseghian C, Raymond VM, Dasari A, Pereira AAL, Willis J, Loree JM, Bauer TM, Chae YK, Sherrill G, Fanta P, Grothey A, Hendifar A, Henry D, Mahadevan D, Nezami MA, Tan B, Wainberg ZA, Lanman R, Kopetz S, Morris V. PMID: 33015522; PMCID: PMC7526699.
      View in: PubMed   Mentions: 15     Fields:    
    102. Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. Pancreas. 2019 10; 48(9):1111-1118. Hendifar AE, Ramirez RA, Anthony LB, Liu E. PMID: 31609931; PMCID: PMC6830950.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    103. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. Clin Colorectal Cancer. 2019 12; 18(4):307-309. Gong J, Robertson MD, Kim E, Fakih M, Schrock AB, Tam KW, Burugapalli B, Monjazeb AM, Hendifar AE, Hitchins M, Klempner SJ, Cho M. PMID: 31563511.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    104. Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. Transl Gastroenterol Hepatol. 2019; 4:63. Chuang J, Chao J, Hendifar A, Klempner SJ, Gong J. PMID: 31559344; PMCID: PMC6737389.
      View in: PubMed   Mentions: 8  
    105. Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases. J Surg Oncol. 2019 Nov; 120(6):926-931. Manguso N, Nissen N, Hendifar A, Harit A, Mirocha J, Friedman M, Lipshutz HG, Amersi F. PMID: 31396982.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    106. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. Br J Cancer. 2019 07; 121(3):264-270. Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ. PMID: 31292535; PMCID: PMC6738081.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    107. 18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation. Adv Radiat Oncol. 2019 Oct-Dec; 4(4):613-622. David JM, Yue Y, Blas K, Hendifar A, Kabolizadeh P, Tuli R. PMID: 31681863; PMCID: PMC6817719.
      View in: PubMed   Mentions: 3  
    108. Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea. P T. 2019 Jul; 44(7):424-427. Cook R, Hendifar AE. PMID: 31258314; PMCID: PMC6590927.
      View in: PubMed   Mentions:
    109. Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data. PLoS One. 2019; 14(6):e0218580. Baecker A, Kim S, Risch HA, Nuckols TK, Wu BU, Hendifar AE, Pandol SJ, Pisegna JR, Jeon CY. PMID: 31237889; PMCID: PMC6592596.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    110. Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer. Oncologist. 2019 12; 24(12):e1460-e1466. Neeman E, Gresham G, Ovasapians N, Hendifar A, Tuli R, Figlin R, Shinde A. PMID: 31227648; PMCID: PMC6975959.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    111. Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. BMJ Open Gastroenterol. 2019; 6(1):e000299. Hitchins MP, Vogelaar IP, Brennan K, Haraldsdottir S, Zhou N, Martin B, Alvarez R, Yuan X, Kim S, Guindi M, Hendifar AE, Kalady MF, DeVecchio J, Church JM, de la Chapelle A, Hampel H, Pearlman R, Christensen M, Snyder C, Lanspa SJ, Haile RW, Lynch HT. PMID: 31275589; PMCID: PMC6577308.
      View in: PubMed   Mentions: 4     Fields:    
    112. Stromal hyaluronan accumulation is associated with low tumor grade and nodal metastases in pancreatic ductal adenocarcinoma. Hum Pathol. 2019 08; 90:37-44. Larson BK, Guan M, Placencio V, Tuli R, Hendifar AE. PMID: 31121193.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    113. Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. Adv Radiat Oncol. 2019 Jul-Sep; 4(3):513-519. Guan M, He I, Luu M, David J, Gong J, Placencio-Hickok VR, Reznik RS, Tuli R, Hendifar AE. PMID: 31360808; PMCID: PMC6639761.
      View in: PubMed   Mentions: 4  
    114. Pancreatic cancer 'mismatch' in Lynch syndrome. BMJ Open Gastroenterol. 2019; 6(1):e000274. Hendifar AE, Larson BK, Rojansky R, Guan M, Gong J, Placencio V, Tuli R, Hitchins M. PMID: 31275582; PMCID: PMC6577306.
      View in: PubMed   Mentions: 6     Fields:    
    115. The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clin Transl Med. 2019 Mar 18; 8(1):9. Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R. PMID: 30887236; PMCID: PMC6423251.
      View in: PubMed   Mentions: 48     Fields:    
    116. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019 06; 156(8):2242-2253.e4. Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. PMID: 30836094.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    117. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine. 2019 Feb; 40:375-381. Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A. PMID: 30635165; PMCID: PMC6412162.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    118. Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced pancreatic adenocarcinoma. Phys Imaging Radiat Oncol. 2019 Jan; 9:28-34. Lao Y, David J, Torosian A, Placencio V, Wang Y, Hendifar A, Yang W, Tuli R. PMID: 32190750; PMCID: PMC7079767.
      View in: PubMed   Mentions: 1  
    119. Pancreas Cancer-Associated Weight Loss. Oncologist. 2019 05; 24(5):691-701. Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, Rahib L, Precision Promise Consortium. PMID: 30591550; PMCID: PMC6516128.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    120. Primary Visceral Merkel Cell Carcinoma: A Case Report and Review of the Literature. Am J Dermatopathol. 2018 Dec; 40(12):927-929. Siref A, Hendifar A, Balzer B. PMID: 29894357.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    121. Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. Adv Radiat Oncol. 2019 Apr-Jun; 4(2):302-313. David JM, Kim S, Placencio-Hickok VR, Torosian A, Hendifar A, Tuli R. PMID: 31011675; PMCID: PMC6460104.
      View in: PubMed   Mentions: 3  
    122. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med. 2018 Oct 08; 7(1):32. Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. PMID: 30294755; PMCID: PMC6174117.
      View in: PubMed   Mentions: 17     Fields:    
    123. Long-Term Outcomes after Elective versus Emergency Surgery for Small Bowel Neuroendocrine Tumors. Am Surg. 2018 Oct 01; 84(10):1570-1574. Manguso N, Gangi A, Nissen N, Harit A, Siegel E, Hendifar A, Amersi F. PMID: 30747671.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    124. Utility of Endoscopic Ultrasound-Guided Biopsy for Next-Generation Sequencing of Pancreatic Exocrine Malignancies. Pancreas. 2018 09; 47(8):990-995. Larson BK, Tuli R, Jamil LH, Lo SK, Deng N, Hendifar AE. PMID: 30028448.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    125. Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy. Pancreas. 2018 09; 47(8):e55-e56. Hendifar AE, Delpassand ES, Kittleson MM, Tuli R. PMID: 30113434.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    126. The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. Oncologist. 2019 01; 24(1):54-61. Hendifar AE, Dhall D, Strosberg JR. PMID: 30104288; PMCID: PMC6324634.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    127. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2019 02; 37(1):159-165. Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, Koh B, Barbie D, Hahn WC, Fuchs CS. PMID: 30105668; PMCID: PMC6510909.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    128. Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. NPJ Digit Med. 2018; 1:27. Gresham G, Hendifar AE, Spiegel B, Neeman E, Tuli R, Rimel BJ, Figlin RA, Meinert CL, Piantadosi S, Shinde AM. PMID: 31304309; PMCID: PMC6550281.
      View in: PubMed   Mentions: 67  
    129. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clin Cancer Res. 2018 10 15; 24(20):5018-5027. Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF. PMID: 29954777.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    130. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018 09 01; 36(25):2578-2584. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E, NETTER-1 Study Group. PMID: 29878866; PMCID: PMC6366953.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansCTClinical Trials
    131. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer. 2018 06 04; 6(1):46. Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. PMID: 29866197; PMCID: PMC5987486.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansAnimals
    132. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence. Mod Pathol. 2018 10; 31(10):1523-1531. Marchevsky AM, Hendifar A, Walts AE. PMID: 29802361.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    133. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol. 2018; 2018. Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM. PMID: 30051098; PMCID: PMC6057747.
      View in: PubMed   Mentions: 96     Fields:    
    134. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. Drug Des Devel Ther. 2018; 12:777-786. Gong J, Yan J, Forscher C, Hendifar A. PMID: 29670334; PMCID: PMC5896668.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    135. Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. J Gastrointest Oncol. 2018 Feb; 9(1):17-23. Hendifar AE, Chang JI, Huang BZ, Tuli R, Wu BU. PMID: 29564167; PMCID: PMC5848037.
      View in: PubMed   Mentions: 40  
    136. The Clinicopathological Aspects of Primary Presacral Neuroendocrine Neoplasms: One Center Experience. Pancreas. 2018 01; 47(1):122-129. Yang G, Dhall D, Yu R, Tuli R, Amersi FF, Friedman ML, Nissen NN, Hendifar AE. PMID: 29215535.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    137. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2018 07; 23(7):766-e90. Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. PMID: 29242283; PMCID: PMC6058330.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    138. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2018 02 01; 36(4):359-366. Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. PMID: 29232172.
      View in: PubMed   Mentions: 233     Fields:    Translation:HumansCTClinical Trials
    139. Wearable activity monitors in oncology trials: Current use of an emerging technology. Contemp Clin Trials. 2018 01; 64:13-21. Gresham G, Schrack J, Gresham LM, Shinde AM, Hendifar AE, Tuli R, Rimel BJ, Figlin R, Meinert CL, Piantadosi S. PMID: 29129704.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    140. Multifocality in Small Bowel Neuroendocrine Tumors. J Gastrointest Surg. 2018 02; 22(2):303-309. Gangi A, Siegel E, Barmparas G, Lo S, Jamil LH, Hendifar A, Nissen NN, Wolin EM, Amersi F. PMID: 29119527.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    141. Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point. Clin Ther. 2017 Nov; 39(11):2135-2145. Gong J, Wu D, Chuang J, Tuli R, Simard J, Hendifar A. PMID: 29079389.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    142. Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine Tumors. Am Surg. 2017 Oct 01; 83(10):1174-1178. Manguso N, Johnson J, Harit A, Nissen N, Mirocha J, Hendifar A, Amersi F. PMID: 29391119.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    143. The role of pre-operative imaging and double balloon enteroscopy in the surgical management of small bowel neuroendocrine tumors: Is it necessary? J Surg Oncol. 2018 Feb; 117(2):207-212. Manguso N, Gangi A, Johnson J, Harit A, Nissen N, Jamil L, Lo S, Wachsman A, Hendifar A, Amersi F. PMID: 28940412.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    144. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. Ann Surg Oncol. 2017 Nov; 24(12):3674-3682. Osipov A, Nissen N, Rutgers J, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R. PMID: 28871564.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    145. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. J Nucl Med. 2017 11; 58(11):1793-1796. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K. PMID: 28473600; PMCID: PMC5666645.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    146. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2017 05; 15(5):555-562. Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N. PMID: 28476735.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    147. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol. 2017 Apr 01; 3(4):516-522. Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS. PMID: 27978579; PMCID: PMC5665683.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCTClinical Trials
    148. Private Funding for Pancreatic Cancer Research: More Than a Chip Shot. Gastroenterology. 2017 04; 152(5):918-921.e2. Hendifar AE, Davies L, Tuli R. PMID: 28259790.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    149. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol. 2017 Feb; 8(1):127-138. Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. PMID: 28280617; PMCID: PMC5334038.
      View in: PubMed   Mentions: 31  
    150. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E, NETTER-1 Trial Investigators. PMID: 28076709; PMCID: PMC5895095.
      View in: PubMed   Mentions: 1174     Fields:    Translation:HumansCTClinical Trials
    151. Statins and pancreatic cancer. Oncol Lett. 2017 Mar; 13(3):1035-1040. Gong J, Sachdev E, Robbins LA, Lin E, Hendifar AE, Mita MM. PMID: 28454210; PMCID: PMC5403279.
      View in: PubMed   Mentions: 24  
    152. A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series. Pancreas. 2017 01; 46(1):48-56. Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, Fan X. PMID: 27984486.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    153. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. J Thorac Oncol. 2017 03; 12(3):425-436. Hendifar AE, Marchevsky AM, Tuli R. PMID: 27890494.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    154. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget. 2017 Oct 13; 8(48):83446-83456. Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E, Brody JR. PMID: 29137355; PMCID: PMC5663527.
      View in: PubMed   Mentions: 31     Fields:    
    155. Cultured circulating tumor cells and their derived xenografts for personalized oncology. Asian J Urol. 2016 Oct; 3(4):240-253. Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK. PMID: 29264192; PMCID: PMC5730836.
      View in: PubMed   Mentions: 21  
    156. Targeting mTOR in Pancreatic Ductal Adenocarcinoma. Front Oncol. 2016; 6:99. Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, Hendifar AE. PMID: 27200288; PMCID: PMC4843105.
      View in: PubMed   Mentions: 25  
    157. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. J Gastrointest Oncol. 2016 Apr; 7(2):239-47. Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M, Annamalai A, Nissen NN, Tuli R. PMID: 27034792; PMCID: PMC4783734.
      View in: PubMed   Mentions: 4  
    158. Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. PLoS One. 2016; 11(3):e0152172. Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R. PMID: 27015568; PMCID: PMC4807776.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    159. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol. 2016 Mar; 4(3):315-325. Gong J, Tuli R, Shinde A, Hendifar AE. PMID: 26998283; PMCID: PMC4774516.
      View in: PubMed   Mentions: 23  
    160. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333; PMCID: PMC4592417.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    161. Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015 Apr; 6(2):185-200. Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. PMID: 25830038; PMCID: PMC4311092.
      View in: PubMed   Mentions: 41  
    162. Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer. Med Dosim. 2015; 40(1):47-52. Yang W, Reznik R, Fraass BA, Nissen N, Hendifar A, Wachsman A, Sandler H, Tuli R. PMID: 25445989.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    163. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014 Oct 10; 32(29):3299-306. Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN. PMID: 25185097; PMCID: PMC4588714.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCTClinical Trials
    164. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. Expert Rev Anticancer Ther. 2014 Sep; 14(9):1051-61. Hendifar A, Tan CR, Annamalai A, Tuli R. PMID: 24898788.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    165. Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. Front Physiol. 2014; 5:87. Reznik R, Hendifar AE, Tuli R. PMID: 24624093; PMCID: PMC3939680.
      View in: PubMed   Mentions: 14  
    166. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Front Physiol. 2014; 5:88. Tan CR, Yaffee PM, Jamil LH, Lo SK, Nissen N, Pandol SJ, Tuli R, Hendifar AE. PMID: 24624094; PMCID: PMC3939686.
      View in: PubMed   Mentions: 60  
    167. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014 Apr; 50(6):1137-47. Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N, Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP. PMID: 24512981.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    168. A Rare Case of Primary Gastric HIV-Associated Peripheral T-Cell Lymphoma: Relapsed Disease Treated With Pemetrexed. World J Oncol. 2013 Oct; 4(4-5):217-220. Gong J, Delioukina ML, Hendifar AE. PMID: 29147360; PMCID: PMC5649932.
      View in: PubMed   Mentions:
    169. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC Cancer. 2013 Mar 16; 13:121. Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM. PMID: 23497336; PMCID: PMC3605142.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    170. Moving beyond response criteria: new measures of success in the treatment of sarcomas. Curr Treat Options Oncol. 2012 Sep; 13(3):299-305. Hendifar AE, Ahlmann E, Allison DC, Hu J, Menendez L, Chawla SP. PMID: 22644834.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    171. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. 2012; 2012:704872. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR. PMID: 22550423; PMCID: PMC3329715.
      View in: PubMed   Mentions: 194  
    172. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011 Jun; 2(2):77-84. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ. PMID: 22811834; PMCID: PMC3397601.
      View in: PubMed   Mentions: 103  
    173. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res. 2009 Oct 15; 15(20):6391-7. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ. PMID: 19789331; PMCID: PMC2779768.
      View in: PubMed   Mentions: 104     Fields:    Translation:Humans
    174. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics. 2009 Feb; 19(2):95-102. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y, Zhang W, Lenz HJ. PMID: 18987561.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    175. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol. 2008 Oct; 19(10):1734-41. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM, Lenz HJ. PMID: 18550579; PMCID: PMC2735064.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    176. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. PMID: 18192902.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    177. Myositis ossificans: a case report. Arthritis Rheum. 2005 Oct 15; 53(5):793-5. Hendifar AE, Johnson D, Arkfeld DG. PMID: 16208662.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    Andrew's Networks
    Concepts (366)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (70)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California